The analyst rating from Citi Research for MAOYAN ENT (01896.HK) is based on several key factors:
1. Upcoming Movie Release: The scheduled release of the animated movie "Demon Slayer" on November 14, for which MAOYAN ENT is the distributor, is expected to drive significant box office performance.
2. Strong Global Performance: The movie has already shown robust global box office results, ranking fifth worldwide with over US$677 million, and has become the top international movie in North America.
3. High Demand Indicators: The announcement of the movie has generated considerable interest, as evidenced by over 400,000 'to-watch' clicks recorded on Maoyan Pro within a single day.
4. Holiday Season Impact: With the New Year holiday period starting in late November, any box office outperformance is anticipated to positively impact MAOYAN ENT, given its position as the largest ticketing platform.
5. Target Price and Valuation: Citi Research maintains a Buy rating with a target price of $9.3, based on a 14x adjusted EPS for 2026, indicating confidence in the company's future earnings potential.
These factors collectively contribute to the positive catalyst watch and the Buy rating for MAOYAN ENT.
